Kangas L, Cantell K, Grönroos M, Mäenpää J, Perilä M
Ann Chir Gynaecol Suppl. 1985;199:60-3.
Combinations of interferons (IFNs) and cytostatic drugs were studied in subrenal capsule assay (SRCA) using fresh human ovarian cancer samples. Slight tumour growth inhibition was observed with IFN-alpha and IFN-gamma. The effect was more pronounced if combination IFN-alpha + IFN-gamma was used. Cytostatic drug combination cyclophosphamide + cisplatin + doxorubicin (combination I) was more effective than interferons, and combination methotrexate + tegafur (combination II) was about equal to IFN-alpha. When IFN-alpha was given together with cytostatic drugs, the antitumour effect was diverse: both synergistic and antagonistic effects were found, as well as no evidence of interaction. IFNs did not increase the toxicity of cytostatic drugs. If there is a good correlation between SRCA and clinical results, the combination of IFNs and cytotoxic drugs should be used clinically in connection with a predictive test.
使用新鲜的人类卵巢癌样本，在肾包膜下测定法（SRCA）中研究了干扰素（IFN）与细胞抑制药物的组合。观察到α干扰素和γ干扰素对肿瘤生长有轻微抑制作用。如果使用α干扰素+γ干扰素组合，效果会更明显。细胞抑制药物组合环磷酰胺+顺铂+阿霉素（组合I）比干扰素更有效，甲氨蝶呤+替加氟组合（组合II）与α干扰素效果大致相当。当α干扰素与细胞抑制药物联合使用时，抗肿瘤效果各不相同：既有协同作用，也有拮抗作用，还有无相互作用的证据。干扰素不会增加细胞抑制药物的毒性。如果SRCA与临床结果有良好的相关性，那么干扰素和细胞毒性药物的组合应结合预测性试验在临床上使用。
